article thumbnail

UK agency pilots biobank to study links between genetics and drug side effects

Pharmaceutical Technology

The biobank will work in parallel with the MHRA’s Yellow Card website, which is used for reporting adverse events and side effects caused by medicines and medical devices, per the 25 May announcement. Side effects due to drugs are responsible for one in every 16 hospital admissions in the UK, based on the announcement.

article thumbnail

Tributes as former NICE, MHRA chair Sir Mike Rawlins dies

pharmaphorum

A pharmacologist by training, Rawlins was the founding chairman of health technology assessment (HTA) agency NICE , leading the organisation from its inception in 1999 until 2013, and hired Sir Andrew Dillon to become the organisation’s founding chief executive.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

GSK shelves arthritis blockbuster hope otilimab after lacklustre data

pharmaphorum

GSK licensed otilimab from German biotech MorphoSys in 2013 in a deal valued at up to €423 million, including around €23 million upfront. Daprodustat backed. There has been somewhat better news for GSK for another of its top pipeline prospects – renal anaemia drug daprodustat – although that also came with disappointment.

article thumbnail

Constipation Patients Are Suffering in Silence—Here’s How to Help Them

PM360

Respondents cited the effectiveness and potential side effects of constipation prescriptions as their top considerations when choosing a medication. 1, 2013. In the survey group, 32% of patients had talked to their doctor about prescription constipation treatments, and 31% had tried them. References: 1.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

One aspect that is extremely promising about radiopharmaceutical therapeutics is that they do not give a patient the side effects that are commonly experienced with chemotherapy. He also oversaw the development of Azedra a targeted radiotherapeutic recently approved by the US FDA for the treatment of rare tumors of the adrenal gland.​

article thumbnail

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Medgadget

These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution. For some patients with PTSD, psychotherapy may not be an effective option, they may find talking about their traumatic experience stress inducing, untherapeutic or ineffective.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

Since the publication of the fifth Diagnostic and Statistical Manual of Mental Disorders in 2013, both conditions are grouped under the term FSIAD, which includes reduced arousal and interest. One Phase II trial was completed back in 2013, as per ClinicalTrials.gov. Neither Addyi nor Vyleesi is approved by the EMA.